Aerie Pharmaceuticals Inc AERI:NASDAQ

Last Price$33.22Cboe Real-Time Last Sale as of 12:32PM ET 6/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.50(4.73%)
Bid (Size)$33.16 (100)
Ask (Size)$33.25 (101)
Day Low / High$31.74 - 33.65
Volume198.6 K

View Pharmaceuticals: Other IndustryPeer Comparison as of 06/17/2019


Aerie Pharmaceuticals Inc ( NASDAQ )

Price: $33.22
Change: +1.50 (4.73%)
Volume: 198.6 K
12:32PM ET 6/17/2019

Innoviva Inc ( NASDAQ )

Price: $14.10
Change: -0.01 (0.07%)
Volume: 91.5 K
12:29PM ET 6/17/2019

Madrigal Pharmaceuticals Inc ( NASDAQ )

Price: $98.95
Change: +1.42 (1.46%)
Volume: 64.3 K
12:20PM ET 6/17/2019

Prestige Consumer Healthcare Inc ( NYSE )

Price: $30.96
Change: +0.55 (1.81%)
Volume: 90.7 K
12:32PM ET 6/17/2019

Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $10.54
Change: +0.17 (1.64%)
Volume: 214.7 K
12:32PM ET 6/17/2019

Read more news Recent News

2019 Estimate for Aerie Pharmaceuticals Raised but 2020 Earnings Number Reduced
11:06PM ET 5/27/2019 MT Newswires

Aerie Pharmaceuticals Inc's (NASDAQ:AERI, Recent Price: 39.87) full year forecasted earnings estimates for 2019 and 2020 have been changed. The consensus...

2019 Estimate for Aerie Pharmaceuticals Scaled Up but 2020 Earnings Number Scaled Down
11:06PM ET 5/24/2019 MT Newswires

The full year forecasted earnings estimates for 2019 and 2020 for Aerie Pharmaceuticals Inc (NASDAQ:AERI, Recent Price: 39.87) have been changed. The...

2019 and 2020 Estimates for Aerie Pharmaceuticals Bumped Up but Q2 Earnings Number Drops
11:16PM ET 5/20/2019 MT Newswires

Earnings estimates for Q2 ending June 30, 2019, and the full year forecasts for 2019 and 2020 for the years ending on December 31 for Aerie Pharmaceuticals...

Insider Trends: Aerie Pharmaceuticals Insider Receives Stock Award Sells Portion for Taxes, Slowing 90-Day Buy Trend
5:19PM ET 5/17/2019 MT Newswires

Dr Vicente Anido Jr, Director and CEO, awarded 32,171 shares in Aerie Pharmaceuticals (AERI) and sold 4,145 shares concurrently to meet tax obligations on...

Company Profile

Business DescriptionAerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC. View company web site for more details
Address4301 Emperor Boulevard
Durham, North Carolina 27703
Number of Employees353
Recent SEC Filing06/13/20198-K
Chairman & Chief Executive OfficerVicente J. Anido
President & Chief Operating OfficerThomas A. Mitro
Chief Financial Officer, Secretary & TreasurerRichard J. Rubino
Chief Scientific OfficerCasey C. Kopczynski

Company Highlights

Price Open$31.82
Previous Close$31.72
52 Week Range$31.01 - 74.75
Market Capitalization$1.5 B
Shares Outstanding45.9 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement08/14/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$5.56
Beta vs. S&P 500N/A
Revenue$24.2 M
Net Profit Margin-684.56%
Return on Equity-108.59%

Analyst Ratings as of 06/07/2019

Consensus RecommendationConsensus Icon
Powered by Factset